• 1. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 2. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 3. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 4. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 5. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991

• Solvents and Organic Chemicals Organic Compounds Alkaloids and derivatives Anatoxins Anatoxins
• Solvents and Organic Chemicals Organic Compounds Alkaloids and derivatives Anatoxins

Recent Advances in the Study of (-)-Anatoxin A (CAS: 92142-32-0): Mechanisms, Applications, and Future Directions

(-)-Anatoxin A, a potent neurotoxin with the CAS number 92142-32-0, has garnered significant attention in the field of chemical biology and medicinal research due to its unique pharmacological properties. This secondary metabolite, produced by certain cyanobacteria, acts as a high-affinity agonist for nicotinic acetylcholine receptors (nAChRs), making it a valuable tool for studying neuronal signaling pathways. Recent studies have further elucidated its molecular interactions, potential therapeutic applications, and environmental implications, providing new insights into its role in neuroscience and toxicology.

One of the most notable advancements in the study of (-)-Anatoxin A is the detailed characterization of its binding mechanism to nAChRs. High-resolution X-ray crystallography and molecular dynamics simulations have revealed the precise conformational changes induced by the toxin upon receptor binding. These findings not only enhance our understanding of nAChR activation but also pave the way for the design of novel ligands targeting these receptors. Furthermore, the toxin's selectivity for specific nAChR subtypes has been exploited in the development of probes for neuroimaging and diagnostics.

In addition to its role as a research tool, (-)-Anatoxin A has shown promise in therapeutic applications. Recent preclinical studies have explored its potential in treating neurological disorders such as Alzheimer's disease and Parkinson's disease. By modulating nAChR activity, the toxin could help restore synaptic plasticity and cognitive function in affected individuals. However, challenges related to its toxicity and delivery mechanisms must be addressed before clinical translation can be realized. Researchers are currently investigating synthetic analogs and prodrugs to mitigate these issues while retaining the desired pharmacological effects.

Environmental monitoring and risk assessment of (-)-Anatoxin A have also been a focus of recent research. With increasing reports of cyanobacterial blooms in freshwater systems, the detection and quantification of this toxin have become critical for public health. Advanced analytical techniques, such as liquid chromatography-tandem mass spectrometry (LC-MS/MS), have been optimized for sensitive and specific detection of (-)-Anatoxin A in environmental samples. These methods are now being integrated into surveillance programs to prevent exposure and mitigate the risks associated with contaminated water sources.

Looking ahead, the study of (-)-Anatoxin A is expected to expand into new areas, including its potential role in pain management and addiction therapy. The toxin's ability to modulate nAChRs makes it a candidate for developing non-opioid analgesics and treatments for nicotine dependence. Collaborative efforts between chemists, biologists, and clinicians will be essential to unlock the full potential of this intriguing molecule. As research progresses, the integration of computational modeling, synthetic chemistry, and translational studies will likely yield innovative solutions to current challenges.

In conclusion, (-)-Anatoxin A (CAS: 92142-32-0) continues to be a molecule of great interest in chemical biology and medicinal research. Its unique properties and diverse applications underscore the importance of ongoing studies to fully understand its mechanisms and harness its potential. By addressing the existing limitations and exploring new avenues, researchers can contribute to advancements in neuroscience, therapeutics, and environmental health, ultimately benefiting both scientific knowledge and public welfare.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)